Janux Therapeutics reports developments for a clinical-stage biopharmaceutical business focused on tumor-activated immunotherapies and immune-engaging drug candidates. The company applies its TRACTr, TRACIr and ARM platforms to programs in oncology and autoimmune disease, including PSMA-directed prostate cancer candidates and a CD19-targeted ARM candidate.
Recurring news themes include clinical progress for JANX007, JANX014 and JANX011, portfolio decisions such as the discontinued JANX008 program, financial results and business highlights, collaboration milestones with Bristol Myers Squibb, and leadership or governance updates tied to the company’s clinical development organization.
Janux Therapeutics (Nasdaq: JANX) has announced significant updates to its Board of Directors. Eric Dobmeier and Natasha Hernday have been appointed to the board, bringing extensive operational and business development experience. Eric Dobmeier, former CEO of Chinook Therapeutics, has over 20 years of biotech industry experience. Natasha Hernday, previously Chief Business Officer at Seagen Inc., has a strong track record in strategic partnerships and acquisitions.
Additionally, Jay Lichter, Ph.D., has resigned from the board, and Ronald W. Barrett, Ph.D., a current board member, has been appointed as Chairperson. These changes aim to support Janux's corporate and pipeline strategy as it advances its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms in developing novel immunotherapies for cancer treatment.
Janux Therapeutics, Inc. (Nasdaq: JANX) reported financial results for Q1 2024, highlighting $651.8 million in cash and ongoing enrollment in clinical trials for PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.